JavaScript is disabled in your web browser or browser is too old to support JavaScript. Today almost all web pages contain JavaScript, a scripting programming language that runs on visitor's web browser. It makes web pages functional for specific purposes and if disabled for some reason, the content or the functionality of the web page can be limited or unavailable.

Monday, March 3, 2025

US making COVID antiviral drug more available at test sites

by

1012 days ago
20220526
White House COVID-19 Response Coordinator Dr. Ashish Jha speaks during the daily briefing at the White House in Washington, Tuesday, April 26, 2022. (AP Photo/Susan Walsh)

White House COVID-19 Response Coordinator Dr. Ashish Jha speaks during the daily briefing at the White House in Washington, Tuesday, April 26, 2022. (AP Photo/Susan Walsh)

By ZEKE MILLER | AS­SO­CI­AT­ED PRESS

 

WASH­ING­TON (AP) — The White House on Thurs­day an­nounced more steps to make the an­tivi­ral treat­ment Paxlovid more ac­ces­si­ble across the U.S. as it projects COVID-19 in­fec­tions will con­tin­ue to spread over the sum­mer trav­el sea­son.

The na­tion’s first fed­er­al­ly backed test-to-treat site is open­ing Thurs­day in Rhode Is­land, pro­vid­ing pa­tients with im­me­di­ate ac­cess to the drug once they test pos­i­tive. More fed­er­al­ly sup­port­ed sites are set to open in the com­ing weeks in Mass­a­chu­setts and New York City, both hit by a marked rise in in­fec­tions.

Next week, the U.S. will send au­tho­rized fed­er­al pre­scribers to sev­er­al Min­neso­ta-run test­ing sites, turn­ing them in­to test-to-treat lo­ca­tions. Fed­er­al reg­u­la­tors have al­so sent clear­er guid­ance to physi­cians to help them de­ter­mine how to man­age Paxlovid’s in­ter­ac­tions with oth­er drugs, with an eye to­ward help­ing pre­scribers find ways to get the life-sav­ing med­ica­tion to more pa­tients.

De­spite a na­tion­wide surge in COVID-19 cas­es, deaths from the virus have re­mained large­ly sta­ble over the past eight weeks, as vac­cine boost­er shots and wide­ly ac­ces­si­ble treat­ments have helped to delink in­fec­tions and mor­tal­i­ty.

Con­firmed in­fec­tions in the U.S. have quadru­pled since late March, from about 25,000 a day to more than 105,000 dai­ly now. But deaths, which have tend­ed to lag in­fec­tions by three to four weeks over the course of the coro­n­avirus pan­dem­ic, have de­clined steadi­ly and are now plateaued at few­er than 300 per day.

It’s the first time in the course of the pan­dem­ic that the two have not trend­ed to­geth­er, said White House COVID-19 co­or­di­na­tor Dr. Ashish Jha. He called it an im­por­tant de­vel­op­ment in help­ing Amer­i­cans get back to nor­mal life.

“What has been re­mark­able in the lat­est in­crease in in­fec­tions we’re see­ing is how steady se­ri­ous ill­ness and par­tic­u­lar­ly deaths are eight weeks in­to this,” he said. “COVID is no longer the killer that it was even a year ago.”

Jha said that giv­en the wider use of at-home rapid tests, whose re­sults of­ten go un­re­port­ed to pub­lic health of­fi­cials, the true num­ber of dai­ly in­fec­tions is like­ly 200,000 or more — dou­ble the re­port­ed rate — which he said on­ly makes the death rate plateau more sig­nif­i­cant.

He cred­it­ed vac­cines but al­so a more than four-fold in­crease in pre­scrip­tions over the last six weeks for the high­ly ef­fec­tive treat­ment Paxlovid.

Jha said about 25,000 to 30,000 cours­es of Paxlovid are be­ing pre­scribed each day. When ad­min­is­tered with­in five days of symp­toms ap­pear­ing, the drug has been proven to bring about a 90% re­duc­tion in hos­pi­tal­iza­tions and deaths among pa­tients most like­ly to get se­vere dis­ease.

Due to a change in the way Paxlovid is al­lo­cat­ed to states, the num­ber of phar­ma­cies where it is avail­able has dou­bled in the last month to al­most 40,000.

“We are now at a point where I be­lieve fun­da­men­tal­ly most COVID deaths are pre­ventable, that the deaths that are hap­pen­ing out there are most­ly un­nec­es­sary, and there are a lot of tools we have now to make sure peo­ple do not die of this dis­ease,” Jha told The As­so­ci­at­ed Press on Wednes­day.

As the sum­mer months ap­proach, Jha said the “num­ber one” thing peo­ple need to do is to “go and get boost­ed” — and if they have a break­through in­fec­tion, they should con­sult with their doc­tor about get­ting Paxlovid. He said gath­er­ings of all sizes can take place more safe­ly be­cause of the tools avail­able — if peo­ple make use of them.

“In places in the coun­try where boost­ing rates are much low­er, where the in­fec­tion is start­ing to spread more, I am ab­solute­ly con­cerned that we’re go­ing to see, un­for­tu­nate­ly, we may see more se­ri­ous ill­ness,” he said.

“Be­ing vac­ci­nat­ed and boost­ed is a huge part of mak­ing sure that those kinds of ac­tiv­i­ties are sub­stan­tial­ly safer,” he added. “And then, of course, we want to make Paxlovid as wide­ly avail­able across the en­tire coun­try, so that if you do end up get­ting a break­through in­fec­tion, you’re still pro­tect­ed against se­ri­ous ill­ness.”

The U.S. has or­dered 20 mil­lion cours­es of Paxlovid from the drug­mak­er Pfiz­er, and the coun­try risks run­ning out this win­ter if the drug con­tin­ues to be used wide­ly. The White House has been press­ing Con­gress for ad­di­tion­al funds for months to sup­port pur­chas­ing more Paxlovid and oth­er treat­ments, as well as ad­di­tion­al boost­ers.

While the ad­min­is­tra­tion has start­ed plan­ning for the po­ten­tial need to ra­tion the fed­er­al sup­ply of vac­cines if Con­gress doesn’t act, Jha said right now his mes­sage to pre­scribers is that they shouldn’t wor­ry about the sup­ply.

“I be­lieve that we should be us­ing as much as it’s nec­es­sary to pro­tect Amer­i­cans now,” Jha said.

COVID-19HealthUnited StatesUnited States of America


Related articles

Sponsored

Weather

PORT OF SPAIN WEATHER

Sponsored